This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.Cost effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 27: 4776-4783, No. 35, 30 Jun 2009
Rights and permissions
About this article
Cite this article
HPV vaccination, a cost-effective strategy in The Netherlands. Pharmacoecon. Outcomes News 586, 9 (2009). https://doi.org/10.2165/00151234-200905860-00023
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905860-00023